法国首例免疫功能低下患者接受 sipavibart 早期准入治疗 COVID-19 暴露前预防的特征。
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France.
机构信息
Virulence Bactérienne et Infections Chroniques, University Montpellier, Nîmes, France.
Service des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, France.
出版信息
Hum Vaccin Immunother. 2024 Dec 31;20(1):2387221. doi: 10.1080/21645515.2024.2387221. Epub 2024 Aug 14.
Abstract
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
摘要
法国是 2023 年 12 月第一个批准 Sipavibart（AZD3152，一种研究性长效单克隆抗体）作为免疫功能低下个体 COVID-19 暴露前预防治疗的国家。接受 Sipavibart 的首批患者具有不同的特征，但他们都存在严重免疫功能低下，经常伴有低丙种球蛋白血症和其他慢性疾病。未报告不良事件。
相似文献
1
Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2387221. doi: 10.1080/21645515.2024.2387221. Epub 2024 Aug 14.
2
Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.
Viruses. 2024 Aug 22;16(8):1345. doi: 10.3390/v16081345.
3
Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan.
J Infect Chemother. 2025 Jan;31(1):102467. doi: 10.1016/j.jiac.2024.07.007. Epub 2024 Jul 8.
4
5
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.
6
"REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
Vaccine. 2024 Oct 3;42(23):126208. doi: 10.1016/j.vaccine.2024.126208. Epub 2024 Aug 17.
7
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2428011. doi: 10.1080/21645515.2024.2428011. Epub 2024 Nov 22.
8
Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.
JAMA. 2021 Nov 16;326(19):1895-1897. doi: 10.1001/jama.2021.19534.
9
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.
J Antimicrob Chemother. 2022 Sep 30;77(10):2688-2692. doi: 10.1093/jac/dkac253.
10
COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
PLoS Med. 2022 Jan 28;19(1):e1003917. doi: 10.1371/journal.pmed.1003917. eCollection 2022 Jan.
引用本文的文献
1
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease.
Sci Rep. 2025 Aug 18;15(1):30244. doi: 10.1038/s41598-025-15641-1.
2
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10).
Leukemia. 2025 Jun 2. doi: 10.1038/s41375-025-02649-9.
本文引用的文献
1
Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study.
Lancet Reg Health Eur. 2023 Oct 13;35:100747. doi: 10.1016/j.lanepe.2023.100747. eCollection 2023 Dec.
2
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
3
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
Zotero 插件